196 related articles for article (PubMed ID: 30136761)
1. Ter-cell, A New Target for Hepatocellular Carcinoma Therapy.
Cen X; Cheng K
Chembiochem; 2018 Nov; 19(21):2254-2256. PubMed ID: 30136761
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression.
Han Y; Liu Q; Hou J; Gu Y; Zhang Y; Chen Z; Fan J; Zhou W; Qiu S; Zhang Y; Dong T; Li N; Jiang Z; Zhu H; Zhang Q; Ma Y; Zhang L; Wang Q; Yu Y; Li N; Cao X
Cell; 2018 Apr; 173(3):634-648.e12. PubMed ID: 29606356
[TBL] [Abstract][Full Text] [Related]
3. [Current advances in molecular targeted therapy of primary hepatocellular carcinoma].
Yu L; Dai Z; Zhou J; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):475-7. PubMed ID: 19567036
[No Abstract] [Full Text] [Related]
4. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma.
Yang N; Li S; Li G; Zhang S; Tang X; Ni S; Jian X; Xu C; Zhu J; Lu M
Oncotarget; 2017 Jan; 8(2):3683-3695. PubMed ID: 27713136
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
Lin D; Wu J
World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
[TBL] [Abstract][Full Text] [Related]
6. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
[TBL] [Abstract][Full Text] [Related]
7. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
Frau M; Biasi F; Feo F; Pascale RM
Mol Aspects Med; 2010 Apr; 31(2):179-93. PubMed ID: 20176048
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
9. Autophagy induction by xanthoangelol exhibits anti-metastatic activities in hepatocellular carcinoma.
Yang X; Xie J; Liu X; Li Z; Fang K; Zhang L; Han M; Zhang Z; Gong Z; Lin X; Shi X; Gao H; Lu K
Cell Biochem Funct; 2019 Apr; 37(3):128-138. PubMed ID: 30883849
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
Gopalan B; Narayanan K; Ke Z; Lu T; Zhang Y; Zhuo L
Biomaterials; 2014 Aug; 35(26):7479-87. PubMed ID: 24912819
[TBL] [Abstract][Full Text] [Related]
11. [Hepatocellular carcinoma].
Kondo S; Ueno H; Morizane C; Okusaka T
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Prenylated Flavonol Derivative as a Pin1 Inhibitor to Suppress Hepatocellular Carcinoma by Modulating MicroRNA Biogenesis.
Zheng Y; Pu W; Li J; Shen X; Zhou Q; Fan X; Yang SY; Yu Y; Chen Q; Wang C; Wu X; Peng Y
Chem Asian J; 2019 Jan; 14(1):130-134. PubMed ID: 30474357
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma.
Tang L; Chen R; Xu X
Cancer Lett; 2020 Apr; 476():120-128. PubMed ID: 32070778
[TBL] [Abstract][Full Text] [Related]
14. Role of the microenvironment in hepatocellular carcinoma development and progression.
Wu SD; Ma YS; Fang Y; Liu LL; Fu D; Shen XZ
Cancer Treat Rev; 2012 May; 38(3):218-25. PubMed ID: 21763074
[TBL] [Abstract][Full Text] [Related]
15. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.
Vilchez V; Turcios L; Marti F; Gedaly R
World J Gastroenterol; 2016 Jan; 22(2):823-32. PubMed ID: 26811628
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic targets and predictive markers for hepatocellular carcinoma.
Chan SL; Chan AW; Yeo W
Expert Opin Ther Targets; 2015 Jul; 19(7):973-83. PubMed ID: 25910512
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes.
Jang JW; Song Y; Kim KM; Kim JS; Choi EK; Kim J; Seo H
BMC Cancer; 2016 Oct; 16(1):810. PubMed ID: 27756242
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.
Lee SJ; Lim HY
Expert Opin Emerg Drugs; 2017 Jun; 22(2):191-200. PubMed ID: 28506080
[TBL] [Abstract][Full Text] [Related]
19. Targeting integrins in hepatocellular carcinoma.
Wu Y; Qiao X; Qiao S; Yu L
Expert Opin Ther Targets; 2011 Apr; 15(4):421-37. PubMed ID: 21332366
[TBL] [Abstract][Full Text] [Related]
20. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
